Free Trial

Wells Fargo & Company's Rating of Alnylam Pharmaceuticals on 10/30/2026

On October 30, 2026, Wells Fargo & Company updated its outlook on Alnylam Pharmaceuticals (NASDAQ:ALNY) with the action "Lower Price Target", setting a price target of $220.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wells Fargo & Company

DateCompanyAction
11/11/2026
Cigna Group stock logo
CI
Cigna Group
Set Price Target
11/11/2026
Veeva Systems Inc. stock logo
VEEV
Veeva Systems
Boost Price Target
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price Target
11/11/2026
EquipmentShare.com Inc stock logo
EQPT
EquipmentShare.com
Lower Price Target
11/11/2026
The Trade Desk stock logo
TTD
Trade Desk
Boost Price Target
11/11/2026
Wix.com Ltd. stock logo
WIX
Wix.com
Lower Price Target
More Ratings From Wells Fargo & Company